US Bancorp
GMAB icon

US Bancorp’s Genmab GMAB Stock Holding History

US Bancorp’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.43M Sell
88,420
-7,128
-7% -$189K ﹤0.01% 856
2026
Q1 		$2.56M Sell
95,548
-33,795
-26% -$1.01M ﹤0.01% 796
2025
Q4 		$3.98M Buy
129,343
+15,493
+14% +$483K ﹤0.01% 664
2025
Q3 		$3.49M Buy
113,850
+25,692
+29% +$626K ﹤0.01% 701
2025
Q2 		$1.82M Sell
88,158
-19,395
-18% -$398K ﹤0.01% 889
2025
Q1 		$2.11M Sell
107,553
-56,995
-35% -$1.2M ﹤0.01% 831
2024
Q4 		$3.43M Sell
164,548
-7,121
-4% -$156K ﹤0.01% 695
2024
Q3 		$4.19M Buy
171,669
+23,723
+16% +$634K 0.01% 633
2024
Q2 		$3.72M Sell
147,946
-1,736
-1% -$49.2K 0.01% 648
2024
Q1 		$4.48M Sell
149,682
-9,396
-6% -$276K 0.01% 608
2023
Q4 		$5.07M Sell
159,078
-22,652
-12% -$711K 0.01% 568
2023
Q3 		$6.41M Buy
181,730
+81,213
+81% +$3.09M 0.01% 496
2023
Q2 		$3.82M Buy
100,517
+3,914
+4% +$156K 0.01% 609
2023
Q1 		$3.65M Sell
96,603
-1,522
-2% -$58.5K 0.01% 626
2022
Q4 		$4.16M Buy
98,125
+5,614
+6% +$231K 0.01% 584
2022
Q3 		$2.97M Buy
92,511
+33,531
+57% +$1.18M 0.01% 643
2022
Q2 		$1.92M Sell
58,980
-19,731
-25% -$639K ﹤0.01% 831
2022
Q1 		$2.85M Buy
78,711
+2,687
+4% +$92.2K ﹤0.01% 749
2021
Q4 		$3.01M Buy
76,024
+1,494
+2% +$62.3K ﹤0.01% 764
2021
Q3 		$3.26M Buy
74,530
+12,909
+21% +$580K 0.01% 699
2021
Q2 		$2.52M Buy
61,621
+35,846
+139% +$1.38M ﹤0.01% 799
2021
Q1 		$846K Buy
25,775
+2,785
+12% +$105K ﹤0.01% 1221
2020
Q4 		$936K Sell
22,990
-29,661
-56% -$1.11M ﹤0.01% 1132
2020
Q3 		$1.93M Buy
52,651
+45,769
+665% +$1.65M ﹤0.01% 762
2020
Q2 		$233K Buy
6,882
+115
+2% +$3.13K ﹤0.01% 1673
2020
Q1 		$143K Sell
6,767
-172
-2% -$3.83K ﹤0.01% 1836
2019
Q4 		$155K Buy
6,939
+1,727
+33% +$37.7K ﹤0.01% 1967
2019
Q3 		$105K Buy
+5,212
New +$103K ﹤0.01% 2134

Other funds holding GMAB

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

US Bancorp's GMAB Position: Q2 2026 in Review

US Bancorp reduced its Genmab (GMAB) stake by 7.5% in Q2 2026, selling an estimated $189K and leaving 88,420 shares worth $2.43M. The position accounts for ﹤0.01% of the portfolio, ranked #856.

US Bancorp first reported a position in GMAB in Q3 2019 and has held it in 28 quarters since. The position peaked at $6.41M in Q3 2023. 289 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • US Bancorp held 88,420 shares of Genmab worth $2.43M as of Q2 2026.
  • US Bancorp sold 7,128 Genmab shares in Q2 2026, an estimated $189K.
  • Genmab made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #856 holding.
  • US Bancorp first reported a position in Genmab in Q3 2019 and has held it in 28 quarters since.
  • US Bancorp's Genmab position peaked at $6.41M in Q3 2023.
  • 289 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.